Anzeige
Mehr »
Dienstag, 01.07.2025 - Börsentäglich über 12.000 News
Diese KI-Biotech-Aktie revolutioniert die Krebstherapie: Lernen Sie Rakovina Therapeutics kennen
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
123 Leser
Artikel bewerten:
(0)

Lipofoods Joins Health Business of Lubrizol Life Science

BARCELONA, Jan. 28, 2020 /PRNewswire/ -- On January 1, Lipofoods SLU became a part of the Health Business of Lubrizol Life Science (LLS Health), strengthening the organization's global presence and providing support to advance its growth in the rapidly developing nutraceutical market.

Lipofoods Joins Health Business of Lubrizol Life Science

The Lipofoods brand, was previously part of the Lubrizol Life Science Beauty business. Lipofoods Nutraceutical Ingredients is now the umbrella brand for the new Nutraceutical Division within LLS Health and includes all existing brands and product platforms for microencapsulated minerals and botanicals. The transition gives the Lipofoods brand strong global infrastructure for driving more innovative solutions to the expanding nutraceuticals market.

"Over the last few years, the Lipofoods brand has experienced rapid growth and scale-up," says David Padró, Business Unit Manager of the Nutraceuticals Division of LLS Health. "This has propelled the need for a larger structure to meet the demands of the fast-changing, highly segmented global nutraceuticals marketplace. This new structure will bring technology and scientific support to active ingredients with functional performance attributes."

The newly formed Nutraceutical Division will leverage the broad range of internal Lubrizol capabilities for improving bioavailability and oral delivery for its portfolio of active ingredients. It will benefit from LLS Health's technological platforms, well established applications expertise, global sales and marketing structures, operations and regulatory know-how to continue developing the nutraceuticals market, while keeping the current sales structure and distribution network.

"The addition of the Lipofoods brand to our portfolio will boost Lubrizol's exposure to the nutraceuticals market and complement our product offerings in the health and wellness industry," adds Barbara Morgan, Global Business Director for Pharmaceutical Solutions of LLS Health. "This illustrates our holistic commitment to improve health outcomes by providing expertise that accelerates customers' growth through expanded access to innovative nutraceutical platforms."

About Lubrizol Life Science - Health

The Health business team at Lubrizol Life Science partners with customers to speed their innovative medical devices and differentiated pharmaceutical products to market. Our dedicated team provides best-in-class polymers and excipients, along with state-of-the-art product design, development, and manufacturing services, with the ultimate goal of creating solutions that improve patient outcomes. For more information about the Health business of Lubrizol Life Science, visit www.Lubrizol.com/Health.

About The Lubrizol Corporation

The Lubrizol Corporation, a Berkshire Hathaway company, is a market-driven global company that combines complex, specialty chemicals to optimize the quality, performance and value of customers' products while reducing their environmental impact. It is a leader at combining market insights with chemistry and application capabilities to deliver valuable solutions to customers in the global transportation, industrial and consumer markets. Lubrizol improves lives by acting as an essential partner in our customers' success, delivering efficiency, reliability or wellness to their end users. Technologies include lubricant additives for engine oils, driveline and other transportation-related fluids, industrial lubricants, as well as additives for gasoline and diesel fuel. In addition, Lubrizol makes ingredients and additives for home care, personal care and skin care products and specialty materials encompassing polymer and coatings technologies, along with polymer-based pharmaceutical and medical device solutions.

With headquarters in Wickliffe, Ohio, Lubrizol owns and operates manufacturing facilities in 17 countries, as well as sales and technical offices around the world. Founded in 1928, Lubrizol has approximately 8,700 employees worldwide. Revenues for 2018 were $6.8 billion. For more information, visit Lubrizol.com.

For more information, contact:

Company contact:
Lubrizol Life Science
Isabel Gómez
Lipofoods Marketing manager
Email: Isabel.Gomez@Lubrizol.com
Twitter: @Lipofoods
Website: www.lipofoods.com

Press Contact:
NutriPR
Liat Simha
Tel: +972-9-9742893
E-mail: liat@nutripr.com
Twitter: @NutriPR
Website: www.nutripr.com

Photo: https://mma.prnewswire.com/media/1082987/Lipofoods_Joins_Health_Business_Lubrizol.jpg

© 2020 PR Newswire
Zeitenwende! 3 Uranaktien vor der Neubewertung
Ende Mai leitete US-Präsident Donald Trump mit der Unterzeichnung mehrerer Dekrete eine weitreichende Wende in der amerikanischen Energiepolitik ein. Im Fokus: der beschleunigte Ausbau der Kernenergie.

Mit einem umfassenden Maßnahmenpaket sollen Genehmigungsprozesse reformiert, kleinere Reaktoren gefördert und der Anteil von Atomstrom in den USA massiv gesteigert werden. Auslöser ist der explodierende Energiebedarf durch KI-Rechenzentren, der eine stabile, CO₂-arme Grundlastversorgung zwingend notwendig macht.

In unserem kostenlosen Spezialreport erfahren Sie, welche 3 Unternehmen jetzt im Zentrum dieser energiepolitischen Neuausrichtung stehen, und wer vom kommenden Boom der Nuklearindustrie besonders profitieren könnte.

Holen Sie sich den neuesten Report! Verpassen Sie nicht, welche Aktien besonders von der Energiewende in den USA profitieren dürften, und laden Sie sich das Gratis-PDF jetzt kostenlos herunter.

Dieses exklusive Angebot gilt aber nur für kurze Zeit! Daher jetzt downloaden!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.